Austria
QUANTRO Therapeutics GmbH, founded in 2019, is a pioneering biotechnology and pharmaceutical company based in Austria. The company is driven by its mission to revolutionize the slogan: "Discovery and development of novel therapeutics targeting transcription factors in cancer and other diseases".
The company emerges from Vienna's renowned Institute of Molecular Biotechnology and Research Institute of Molecular Pathology, leveraging advanced techniques like time-resolved RNA sequencing and comparative transcriptomics. These tools empower QUANTRO to tackle cancer-associated transcription factors, paving the way for innovative drug candidates previously beyond the reach of pharmacological intervention.
In its latest funding milestone, QUANTRO received a €1.70M grant from The Austrian Research Promotion Agency (FFG) as of 06 August 2024. This investment enhances their research and development capabilities, affirming their potential to address previously challenging targets in disease management.
